XNAS
VMD
Market cap356mUSD
Oct 08, Last price
9.41USD
1D
0.43%
1Q
-23.56%
IPO
424.64%
Name
Viemed Healthcare Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Viemed Healthcare, Inc., operating through its subsidiaries, delivers essential at-home durable medical equipment (DME) and specialized post-acute respiratory care services to patients across the United States. The company offers comprehensive management solutions for various respiratory conditions, notably chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapeutic interventions. It provides both invasive and non-invasive ventilation equipment and related supplies, particularly for individuals battling COPD. Viemed also makes available through leasing a wide array of devices such as non-invasive and invasive ventilators, positive airway pressure (PAP) machines, percussion vests, oxygen concentrator units, and other smaller respiratory apparatus. Beyond leasing, it engages in the sale and rental of DME and offers direct patient medical services. The firm further extends its capabilities to encompass neuromuscular care and oxygen therapy. Additionally, Viemed supplies solutions for sleep apnea management, featuring equipment like PAP, automatic continuous positive airway pressure, and bi-level positive airway pressure machines, complemented by at-home sleep apnea testing services. Founded in 2006, Viemed Healthcare, Inc. maintains its headquarters in Lafayette, Louisiana.
Key people
Michael Moore
President · since 2017
Trae Fitzgerald
Chief Financial Officer · since 2017
W. Todd Zehnder
Chief Operating Officer, Director · since 2017
Jeremy Trahan
Chief Legal Officer, Executive Vice President, Corporate Secretary · since 2024
Jerome Cambre
Vice President - Sales · since 2018
William Frazier
Chief Medical Officer, Director · since 2017
Casey Hoyt
Chief Executive Officer, Director · since 2016
Randy Dobbs
Independent Chairman of the Board · since 2017
Sabrina Heltz
Independent Director · since 2020
Independent Director · since 2017
Timothy Smokoff
Independent Director · since 2017
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||